Collegium Pharmaceutical (COLL) Cash & Equivalents (2014 - 2026)

Collegium Pharmaceutical's Cash & Equivalents history runs 13 years deep, the most recent figure standing at $268.6 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 179.28% year-over-year to $268.6 million; the TTM figure through Mar 2026 stood at $268.6 million (up 179.28% YoY), while the FY2025 annual figure was $231.3 million, up 227.71% from the prior year.
• Cash & Equivalents was $268.6 million for Q1 2026 at Collegium Pharmaceutical, up from $231.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $283.7 million in Q2 2023 to a low of $39.0 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $174.3 million across 5 years, with a median of $172.9 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents plunged 84.93% in 2024, then surged 285.26% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $173.7 million in 2022, then surged by 37.57% to $238.9 million in 2023, then sank by 70.47% to $70.6 million in 2024, then surged by 227.71% to $231.3 million in 2025, then advanced by 16.17% to $268.6 million in 2026.
• The last three Cash & Equivalents figures came in at $268.6 million (Q1 2026), $231.3 million (Q4 2025), and $150.1 million (Q3 2025), per Business Quant data.